Zymeworks (ZYME) closed at $25.84 on November 17, 2026, down 2.3% from the previous close, on volume of 528,715 shares (30-day average 1,332,325).
Data as of November 17, 2026.
17-Nov-2026
Zymeworks Authorizes New $200 Million Share Repurchase Program
TipRanks (Mon, 16-Nov 7:00 AM ET)
Zymeworks authorizes up to $200M in share repurchases
Seeking Alpha News (Mon, 16-Nov 6:16 AM ET)
Zymeworks Announces $200 Million Share Repurchase Authorization
Globe Newswire (Mon, 16-Nov 6:00 AM ET)
Zymeworks (ZYME) Gets a Buy from J.P. Morgan
TipRanks (Fri, 13-Nov 7:16 AM ET)
Zymeworks Provides Corporate Update and Reports Third Quarter 2026 Financial Results
Globe Newswire (Mon, 9-Nov 4:05 PM ET)
Business Wire (Tue, 27-Oct 7:00 AM ET)
Globe Newswire (Sat, 24-Oct 2:30 AM ET)
Globe Newswire (Fri, 23-Oct 6:00 AM ET)
Globe Newswire (Mon, 19-Oct 6:00 AM ET)
Globe Newswire (Thu, 15-Oct 6:00 AM ET)
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Zymeworks trades on the NASDAQ stock market under the symbol ZYME.
As of November 17, 2026, ZYME stock price declined to $25.84 with 528,715 million shares trading.
ZYME has a beta of -0.14, meaning it tends to be less sensitive to market movements. ZYME has a correlation of 0.00 to the broad based SPY ETF.
ZYME has a market cap of $1.81 billion. This is considered a Small Cap stock.
Last quarter Zymeworks reported $256 million in Revenue and $2.28 earnings per share. This beat revenue expectation by $30 million and exceeded earnings estimates by $.05.
In the last 3 years, ZYME traded as high as $31.97 and as low as $7.97.
The top ETF exchange traded funds that ZYME belongs to (by Net Assets): VTI, IWM, IBB, IWO, DFAS.
ZYME has underperformed the market in the last year with a price return of +8.1% while the SPY ETF gained +11.2%. However, in the short term, ZYME had mixed performance relative to the market. It has outperformed in the last 3 months, returning +2.1% vs -5.0% return in SPY. But in the last 2 weeks, ZYME shares have been beat by the market, returning -14.2% compared to an SPY return of -2.9%.
ZYME support price is $25.52 and resistance is $27.39 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ZYME shares will trade within this expected range on the day.